Hirotaka Nagasaka, Takeshi Kishida, Taku Kouro, Yuka Igarashi, Shinichi Takebe, Shotaro Yamamoto, Takuya Kondo, Mitsuyuki Koizumi, Hideyuki Terao, Takahisa Suzuki, et al. MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors. International journal of clinical oncology. 2024
Feifei Wei, Taku Kouro, Yuko Nakamura, Hiroki Ueda, Susumu Iiizumi, Kyoko Hasegawa, Yuki Asahina, Takeshi Kishida, Soichiro Morinaga, Hidetomo Himuro, et al. Enhancing Mass spectrometry-based tumor immunopeptide identification: machine learning filter leveraging HLA binding affinity, aliphatic index and retention time deviation. Computational and Structural Biotechnology Journal. 2024
Yoshiro Nakahara, Taku Kouro, Satoru Motoyama, Masatomo Miura, Kazuma Fujita, Yuka Igarashi, Naoko Higashijima, Norikazu Matsuo, Hidetomo Himuro, Feifei Wei, et al. Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors. Frontiers in Cell and Developmental Biology. 2024
Taku Kouro, Naoko Higashijima, Shun Horaguchi, Yasunobu Mano, Rika Kasajima, Huihui Xiang, Yuki Fujimoto, Hiroyuki Kishi, Hiroshi Hamana, Daisuke Hoshino, et al. Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1. International journal of cancer. 2024
Feifei Wei, Tetsuro Sasada. Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes and immunity. 2023
American Society of Clinical Oncology
, American Association of Immunologists
, Society for Immunotherapy of Cancer
, American Association for Cancer Research
, 日本がん免疫学会
, 日本遺伝子細胞治療学会
, 日本免疫学会
, 日本癌治療学会
, 日本癌学会
, 日本消化器外科学会
, 日本外科学会
, 近畿外科学会